Department: Medicine and Oncology
University: Harvard University
Country: United States
Dr. Hamza Mujagic is former Visiting Scholar and Professor at Massachusetts General Hospital/ Harvard University/Harvard Cancer Center and former Clinical Review Board Member for Harvard University Cancer Center, Boston and former Consultant for Xanthus Pharmaceuticals, Cambridge, Massachusetts, USA. He graduated from the University of Zagreb Medical School in 1968 where he also received his basic clinical training and Board certification in Medicine. He obtained his Master's degree from the University of Zagreb in 1973 and his Ph.D. from the Universities of Essen, Germany, and the University of Zagreb in 1976. He received his specialty training in Nuclear Medicine in 1971-1972 and Clinical Oncology in 1972-1977 from Central Institute for tumors in Zagreb and Internal medicine from several clinical centers in Europe and from the University Medical Center in Sarajevo in 1980. He started his career in Translational Medicine as a Fellow of Scientific Fund of The Republic of Croatia combining his research at Institute Rudjer Boskovic/ University of Zagreb from 1969-1971 and clinical work at University Hospital “Merkur” in1972 and continued his career in translational medicine at Central Institute for tumors in Zagreb from 1971-1977. As a recipient of International Union Against Cancer (ICRETT) Award he worked in the National Cancer Institute/ National Institutes of Health of the USA in Bethesda from 1978-1979. He was then invited to join The National Cancer Institute and worked there from 1980-1984 and continued at the Memorial Sloan-Kettering Cancer Center, New York, from 1984-1985, at the Universities in Banjaluka and Tuzla and as a Visiting Scholar and Professor at Harvard University and Massachusetts General Hospital from 1997 and on, where he has spent most of his last 12 professional years. He is specialist in Internal Medicine/subspecialties Urologic Oncology and Cancer Pharmacology/ Immunology and is Professor of Medicine and Oncology. He published 106 research papers, was or is on the Editorial Boards of 5 international journals, reviewer for several scientific journals and is cited thus far 559 times. His areas of expertise are Urologic, lung, breast, GI and melanoma cancers, design and conduct of Clinical Trials, Cancer Chemotherapy and Immunotherapy, and Cancer drug analysis and writing. His latest working engagement: was as senior Consultant and Professor at Lanssjukhus Sundsvall/Umea University, Department of Oncology, Sundsvall, Sweden. Currently, he is in private practice.
His research interest mainly focuses on Cancer Biology and cancer genomics,Cancer pharmacology and Immunology,Cancer clinical trials,Melanoma,lung,breast,urogenital and gastrointestinal cancers.
Boffin Access Limited is committed to maintaining the integrity of the scholarly record to researchers. Therefore violation of professional ethical codes may lead to retract articles. Article(s) may be retracted if it is found to have serious flaws, reported misconduct research, constitute copyright infringement and plagiarism.
To help avoid the incorrect or misleading publications, please drop your message to
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: firstname.lastname@example.org
Copyright © 2020 Boffin Access Limited.